Drug & Medication
Table of Contents
Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.Detailed analysis of the likely date of generic entry for Cymbalta and RevlimidAnalysis of both products' position in their companies total prescription pharma portfolio...More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Jordan
+1 917 267 7886
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute o ...
PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such as ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of ...
... Hg introduces new recommendations designed to promote safer use of angiotensin converting enzyme inhibitors (aceis) and angiotensin receptor blockers (arbs) first-line and later-line treatment should now ...
... vaccination 1988: before the global polio eradication initiative endemic non-endemic who. Global polio eradication initiative. Available at: http ...
Reportlinker.com © Copyright 2014. All rights reserved.